A pilot non‐inferiority randomized controlled trial to assess automatic adjustments of insulin doses in adolescents with type 1 diabetes on multiple daily injections therapy

Background Multiple daily injections (MDI) therapy for type 1 diabetes involves basal and bolus insulin doses. Non‐optimal insulin doses contribute to the lack of satisfactory glycemic control. We aimed to evaluate the feasibility of an algorithm that optimizes daily basal and bolus doses using gluc...

Full description

Saved in:
Bibliographic Details
Published inPediatric diabetes Vol. 21; no. 6; pp. 950 - 959
Main Authors El Fathi, Anas, Palisaitis, Emilie, Oettingen, Julia E., Krishnamoorthy, Preetha, Kearney, Robert E., Legault, Laurent, Haidar, Ahmad
Format Journal Article
LanguageEnglish
Published Former Munksgaard John Wiley & Sons A/S 01.09.2020
John Wiley & Sons, Inc
Subjects
Online AccessGet full text
ISSN1399-543X
1399-5448
1399-5448
DOI10.1111/pedi.13052

Cover

More Information
Summary:Background Multiple daily injections (MDI) therapy for type 1 diabetes involves basal and bolus insulin doses. Non‐optimal insulin doses contribute to the lack of satisfactory glycemic control. We aimed to evaluate the feasibility of an algorithm that optimizes daily basal and bolus doses using glucose monitoring systems for MDI therapy users. Methods We performed a pilot, non‐inferiority, randomized, parallel study at a diabetes camp comparing basal‐bolus insulin dose adjustments made by camp physicians (PA) and a learning algorithm (LA), in children and adolescents on MDI therapy. Participants wore a glucose sensor and underwent 11 days of daily dose adjustments in either arm. Algorithm adjustments were reviewed and approved by a physician. The last 7 days were examined for outcomes. Results Twenty‐one youths (age 13.3 [SD, 3.7] years; 13 females; HbA1c 8.6% [SD, 1.8]) were randomized to either group (LA [n = 10] or PA [n = 11]). The algorithm made 293 adjustments with a 92% acceptance rate from the camp physicians. In the last 7 days, the time in target glucose (3.9‐10 mmol/L) in LA (39.5%, SD, 20.7) was similar to PA (38.4%, SD, 15.6) (P = .89). The number of hypoglycemic events per day in LA (0.3, IQR, [0.1‐0.6]) was similar to PA (0.2, IQR, [0.0‐0.4]) (P = .42). There was no incidence of severe hypoglycemia nor ketoacidosis. Conclusions In this pilot study, glycemic outcomes in the LA group were similar to the PA group. This algorithm has the potential to facilitate MDI therapy, and longer and larger studies are warranted.
Bibliography:Funding information
Peer Review
Laurent Legault and Ahmad Haidar share senior authorship.
https://publons.com/publon/10.1111/pedi.13052
Anas El Fathi and Emilie Palisaitis have contributed equally to this study.
The peer review history for this article is available at
.
Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada
ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1399-543X
1399-5448
1399-5448
DOI:10.1111/pedi.13052